Unforgiving Wall Street
Investment community is having a hard time reconciling the lost value from the aborted Glaxo Wellcome-SmithKline Beecham merger, SB Chairman Leschly acknowledges. Noting that SB added $56 mil. per day "including Saturdays and Sundays" to its market cap during 1997 before merger talks, Leschly lamented to Wharton New Ventures meeting, "I am still being abused by the institutions"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth